Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Inclusion Criteria: * Individual with HIV-1 * Combination antiretroviral therapy (ART) for at least 180 days prior to study entry * CD4+ cell count greater than 100 cells/mm\^3 * Acceptable screening laboratories including: * Fasting low-density lipoprotein (LDL) cholesterol as follows: * If ASCVD risk score was less than 7.5%, LDL cholesterol must have been less than 190 mg/dL. * If ASCVD risk score was greater than or equal to 7.5% and less than or equal to 10%, LDL must have been less than 160 mg/dL. * If ASCVD risk score was greater than 10% and less than or equal to 15%, LDL must have been less than 130 mg/dL. * Participants with LDL less than 70 mg/dL were eligible regardless of the 10-year ASCVD risk score, in line with the ACC/AHA 2013 Prevention Guidelines. * Fasting triglycerides less than 500 mg/dL * Hemoglobin greater than or equal to 8 g/dL for female participants and greater than or equal to 9 g/dL for male participants * Glomerular filtration rate (GFR) greater than or equal to 60 mL/min/1.73m\^2 or creatinine clearance (CrCl) greater than or equal to 60 mL/min * Alanine aminotransferase (ALT) less than or equal to 2.5 x the upper limit of normal (ULN) * For persons with known chronic active hepatitis B or C, calculated fibrosis 4 score (FIB-4) must have been less than or equal to 3.25 * Ability and willingness of participant or legal representative to provide written informed consent Exclusion Criteria: * Clinical ASCVD, as defin…